MBX BIOSCIENCES INC (MBX)

Initiation of Phase 2 Study for MBX 1416 Expected

MBX Biosciences, Inc. announced plans to initiate a Phase 2 clinical study of MBX 1416 aimed at treating post-bariatric hypoglycemia (PBH), anticipatable in the second half of 2025. This decision follows favorable results from a Phase 1 trial, where MBX 1416 demonstrated a good safety profile and pharmacodynamic effects that may provide therapeutic benefits to patients diagnosed with PBH. As of December 31, 2024, MBX's financial position includes cash, cash equivalents, and marketable securities totaling $262.1 million. The company is classified as an emerging growth entity and is currently undergoing an audit of its 2024 financial statements.